Rummel, Mathias

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Kayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H. A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., et al. (2011) · Blood

Acute Myeloid Leukemia ResearchMultiple and Secondary Primary Cancers

Cited by 487

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

Rummel, M., Kim, T. M., Aversa, F., Brugger, W., Capochiani, E., Plenteda, C., Re, F., Trask, P., Osborne, S., Smith, R., et al. (2017) · Annals of Oncology

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 154

Completed induction phase analysis of MAGNIFY: phase 3b study of lenalidomide + rituximab (R 2) followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma

Lansigan, F., Andorsky, D. J., Coleman, M., Yacoub, A., Melear, J., Fanning, S., Kolibaba, K. S., Reynolds, C. M., Nowakowski, G. S., Gharibo, M., et al. (2021) · Blood

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 14